Instrument Inactif

Communiqués HLS Therapeutics Inc Toronto S.E.

Actions

AM

CA05328X1015

Produits pharmaceutiques

Communiqués

26/06	HLS Therapeutics Reports Annual Meeting Results	AQ
23/06	HLS Therapeutics Announces Normal Course Issuer Bid	AQ
15/05	HLS Therapeutics : First Quarter 2026 Presentation	PU
15/05	HLS Therapeutics Announces Q1 2026 Financial Results	AQ
01/05	HLS Therapeutics to Host Q1 2026 Financial Results Conference Call	AQ
23/04	HLS Therapeutics : Investor Presentation	PU
14/04	HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference	AQ
12/03	HLS Therapeutics : 2026 Annual Report 2026 Annual Information Form	PU
12/03	HLS Therapeutics Announces Fiscal 2025 Financial Results	AQ
26/02	HLS Therapeutics to Host Fiscal 2025 Financial Results Conference Call	AQ
13/11	HLS Therapeutics : Q3 2025 Conference Call Presentation	PU
13/11	HLS Therapeutics : Third Quarter 2025 MD&A	PU
13/11	HLS Therapeutics Announces Q3 2025 Financial Results	AQ
30/10/25	HLS Therapeutics to Host Q3 2025 Financial Results Conference Call	AQ
14/10/25	HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress	AQ
20/08/25	HLS Therapeutics Announces New Credit Agreement	AQ
14/08/25	HLS Therapeutics : Q2 2025 Conference Call Presentation	PU
31/07/25	HLS Therapeutics to Host Q2 2025 Financial Results Conference Call	AQ
02/07/25	HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan	AQ
20/06/25	HLS Therapeutics Reports Annual Meeting Results	AQ
28/04/25	HLS Therapeutics to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference	AQ
24/04/25	HLS Therapeutics to Host Q1 2025 Financial Results Conference Call	AQ
13/03/25	HLS Therapeutics : Q4 2024 Conference Call Presentation	PU
13/03/25	HLS Therapeutics : Fourth Quarter 2024 MD&A	PU
13/03/25	HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid	AQ